These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35185589)

  • 1. Evaluation of JQ1 Combined With Docetaxel for the Treatment of Prostate Cancer Cells in 2D- and 3D-Culture Systems.
    Xu Y; Pachnikova G; Przybilla D; Schäfer R; Cui Y; Zhou D; Chen Z; Zhao A; Keilholz U
    Front Pharmacol; 2022; 13():839620. PubMed ID: 35185589
    [No Abstract]   [Full Text] [Related]  

  • 2. IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation.
    Xu Y; Pachnikova G; Wang H; Wu Y; Przybilla D; Schäfer R; Chen Z; Zhu S; Keilholz U
    Bosn J Basic Med Sci; 2022 Jul; 22(4):580-592. PubMed ID: 35694767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
    Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
    Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of docetaxel on metastatic prostate (DU-145) carcinoma cells cultured as 2D monolayers and 3D multicellular tumor spheroids.
    Fujiike AY; de Oliveira LCB; Ribeiro DL; Pereira ÉR; Okuyama NCM; Dos Santos AGP; de Syllos Cólus IM; Serpeloni JM
    J Toxicol Environ Health A; 2024 Mar; 87(6):227-244. PubMed ID: 38095149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment.
    Ko J; Meyer AN; Haas M; Donoghue DJ
    Oncotarget; 2021 Jan; 12(1):22-36. PubMed ID: 33456711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures.
    Mosaad E; Chambers K; Futrega K; Clements J; Doran MR
    BMC Cancer; 2018 May; 18(1):592. PubMed ID: 29793440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Infiltrating mast cells promote neuroendocrine differentiation and increase docetaxel resistance of prostate cancer cells by up-regulating p21].
    Ou YH; Jiang YD; Li Q; Zhuang YJ; Dang Q; Tan WL
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Jun; 38(6):723-730. PubMed ID: 29997096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
    Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
    Li X; Wu JB; Chung LW; Huang WC
    Oncotarget; 2015 Dec; 6(38):41018-32. PubMed ID: 26512780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
    Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
    Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes.
    Grayson KA; Jyotsana N; Ortiz-Otero N; King MR
    PLoS One; 2021; 16(3):e0246733. PubMed ID: 33661931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Combination of Omega-3 Stearidonic Acid and Docetaxel Enhances Cell Death over Docetaxel Alone in Human Prostate Cancer Cells.
    Mansour M; van Ginkel S; Dennis JC; Mason B; Elhussin I; Abbott K; Pondugula SR; Samuel T; Morrison E
    J Cancer; 2018; 9(23):4536-4546. PubMed ID: 30519360
    [No Abstract]   [Full Text] [Related]  

  • 13. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
    Asangani IA; Dommeti VL; Wang X; Malik R; Cieslik M; Yang R; Escara-Wilke J; Wilder-Romans K; Dhanireddy S; Engelke C; Iyer MK; Jing X; Wu YM; Cao X; Qin ZS; Wang S; Feng FY; Chinnaiyan AM
    Nature; 2014 Jun; 510(7504):278-82. PubMed ID: 24759320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prazosin but Not Tamsulosin Sensitises PC-3 and LNCaP Prostate Cancer Cells to Docetaxel.
    Spencer BH; McDermott CM; Chess-Williams R; Christie D; Anoopkumar-Dukie S
    Pharmacology; 2018 Apr; 102(1-2):10-18. PubMed ID: 29669348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
    Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
    Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
    Eftekhari S; Montazeri H; Tarighi P
    Eur J Pharmacol; 2020 Jul; 878():173102. PubMed ID: 32283060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
    Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
    Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of collagen-based scaffolds to simulate prostate cancer bone metastases with potential for evaluating delivery of nanoparticulate gene therapeutics.
    Fitzgerald KA; Guo J; Tierney EG; Curtin CM; Malhotra M; Darcy R; O'Brien FJ; O'Driscoll CM
    Biomaterials; 2015 Oct; 66():53-66. PubMed ID: 26196533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.
    Kroon J; Puhr M; Buijs JT; van der Horst G; Hemmer DM; Marijt KA; Hwang MS; Masood M; Grimm S; Storm G; Metselaar JM; Meijer OC; Culig Z; van der Pluijm G
    Endocr Relat Cancer; 2016 Jan; 23(1):35-45. PubMed ID: 26483423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-derived, three-dimensional spheroid cultures provide a versatile translational model for the study of organ-confined prostate cancer.
    Linxweiler J; Hammer M; Muhs S; Kohn M; Pryalukhin A; Veith C; Bohle RM; Stöckle M; Junker K; Saar M
    J Cancer Res Clin Oncol; 2019 Mar; 145(3):551-559. PubMed ID: 30474758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.